Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001437749-25-031538
Filing Date
2025-10-22
Accepted
2025-10-22 18:11:59
Documents
2
Period of Report
2025-10-21

Document Format Files

Seq Description Document Type Size
1 FORM 3 rdgdoc.html 3  
1 FORM 3 rdgdoc.xml 3 1392
2 poabir.htm EX-24 11898
  Complete submission text file 0001437749-25-031538.txt   14900
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Issuer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O GERON CORPORATION 919 EAST HILLSDALE BOULEVARD, SUITE 250 FOSTER CITY CA 94404
Business Address
Bir Dawn Carter (Reporting) CIK: 0001688712 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-41905 | Film No.: 251411011